A previous publication found that patients with NPM1mut AML who have positive MRD at EOT have a heterogeneous evolution, with a 1-year EFS <50% in patients with failure to clear MRD below 4.4 log10 from baseline and/or FLT3-ITD mutation.17 Here, FLT3 is linked to acute myeloid leukemia.